High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Rescue for Pediatric Brain Tumor Patients: A Single Institution Experience from UCLA by Panosyan, Eduard H. et al.
Hindawi Publishing Corporation
Journal of Transplantation
Volume 2011, Article ID 740673, 11 pages
doi:10.1155/2011/740673
Research Article
High-Dose Chemotherapywith Autologous Hematopoietic
Stem-Cell Rescue for Pediatric Brain Tumor Patients: A Single
Institution Experience from UCLA
Ed uar dH.P ano syan,AlanK .I k eda,V i vianY .Ch ang,DanR.Lak s,Ch arlesL.R eeb,
La VetteBowles, Joseph L. Lasky III,and Theodore B. Moore
UCLA Medical Center, Mattel Children’s Hospital, Los Angeles, CA 90095, USA
Correspondence should be addressed to Eduard H. Panosyan, epanosyan@mednet.ucla.edu
Received 20 July 2010; Revised 23 November 2010; Accepted 31 January 2011
Academic Editor: O. Ringd´ en
Copyright © 2011 Eduard H. Panosyan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Dose-dependent response makes certain pediatric brain tumors appropriate targets for high-dose chemotherapy
with autologous hematopoietic stem-cell rescue (HDCT-AHSCR). Methods. The clinical outcomes and toxicities were analyzed
retrospectively for 18 consecutive patients ≤19y/o treated with HDCT-AHSCR at UCLA (1999–2009). Results. Patients’ median
age was 2.3 years. Fourteen had primary and 4 recurrent tumors: 12 neural/embryonal (7 medulloblastomas, 4 primitive
neuroectodermal tumors, and a pineoblastoma), 3 glial/mixed, and 3 germ cell tumors. Eight patients had initial gross-total and
seven subtotal resections. HDCT mostly consisted of carboplatin and/or thiotepa ± etoposide (n = 16). Nine patients underwent a
single AHSCR and nine ≥3 tandems. Three-year progression-free and overall survival probabilities were 60.5%± 16 and 69.3%±
11.5. Ten patients with pre-AHSCR complete remissions were alive/disease-free, whereas 5 of 8 with measurable disease were
deceased (median followup: 2.3 yrs). Nine of 13 survivors avoided radiation. Single AHSCR regimens had greater toxicity than ≥3
AHSCR (P<. 01). Conclusion. HDCT-AHSCR has a deﬁnitive, though limited role for selected pediatric brain tumors with poor
prognosis and pretransplant complete/partial remissions.
1.Introduction
Certain pediatric brain tumors such as those of primitive
neuroectodermal origin have demonstrated dose-dependent
chemotherapy responses [1–3] and the principles of high-
dose chemotherapy with stem-cell rescue have been applied
to these pediatric brain tumors similarly to those of other
solid tumors [4–6]. High-dose chemotherapy with autolo-
gous hematopoietic stem-cell rescue (HDCT-AHSCR) has
been used successfully in children with recurrent/refractory
or poor-prognosis medulloblastomas, primitive neuroecto-
dermal tumors (PNETs), atypical teratoid/rhabdoid tumors,
and central nervous system (CNS) germ cell tumors (GCTs)
[7–17]. However, the eﬃcacy of this treatment strategy for
CNS tumors of glial origin, such as high-grade gliomas
and ependymomas, is less encouraging [18–21]. The HDCT
regimens reported in literature vary but mainly consist of
alkylator-based myeloablation, including thiotepa (TT) with
or without topoisomerase inhibitors [8, 13, 18–20, 22, 23].
Other agents may be rationally implemented in pre-HDCT
chemotherapy depending on tumor type, such as vincristine
(VCR) and methotrexate (MTX) for medulloblastomas or
temozolomide (TMZ) for gliomas [1, 4, 6, 11, 12, 19, 21,
22, 24]. Variable intensity of regimens and numbers of
myeloablations/AHSCRs may potentially result in diﬀerent
outcomes and toxicity proﬁles.
The disease histotypes, HDCT regimens, and patient
c h a r a c t e r i s t i c sh a v ed i ﬀered signiﬁcantly among reported
series [11, 12, 19, 22]. Nevertheless, achieving positive
results generally is more likely in patients with no evidence
of disease/minimal residual disease status at the time
of stem-cell rescue [5, 23]. Because of this, with the
exception of highly chemosensitive lesions like GCTs [13],
the extent of surgical resection may play a crucial role in2 Journal of Transplantation
Table 1: Patient characteristics.
Patient
number
Age at diagnosis
(years)/ Gender Diagnosis, grade Location Primary/ recurrent Highest stage
1 10.9/Male Medulloblastoma, IV Posteriorfossaand Cervical-spine Recurrent M3
2 15.9/Male NGGCT Pineal Primary M0
3 0.9/Male Medulloblastoma, IV Posterior fossa Primary M0
4 17.3/Male NGGCT Pineal Primary M0
52 . 9 / F e m a l e Anaplastic
Oligodendroglioma, III Frontal, Left Primary M0
6 5.3/Male Supratentorial PNET, IV Cerebral, Left Primary M0
7 0.6/Male Medulloblastoma, IV Posterior fossa Primary M2
8 1.2/Female Neurocytoma, II Frontal, Right Recurrent M3
9 18.6/Male NGGCT Pineal Recurrent M3
10 4.4/Female Supratentorial PNET, IV Frontal, Left Primary M0
11 1.8/Male Supratentorial PNET, IV Frontal, Right Primary M0
12 2.2/Male Anaplastic
Ependymoma, III Occipitoparietal, Left Primary M0
13 10.2/Female Pineoblastoma, IV Pineal Recurrent M2
14 0.4/Male Medulloblastoma, IV Posterior fossa Primary M3
15 2.4/Female Medulloblastoma, IV Brainstem Primary M0
16 2.1 /Female Medulloblastoma, IV Posterior fossa Primary M0
17 2.1/Male Supratentorial PNET, IV Frontal, Right Primary M2
18 1.7/Male Medulloblastoma, IV Posterior fossa Primary M2
NGGCT: nongerminomatous germ cell tumor.
PNET: primitive neuroectodermal tumor.
clinical outcomes. Surgery may also be used for second
look pre- or posttransplant evaluations, since MRIs may
reveal treatment-related heterogeneously enhancing lesions
apparently indistinguishable from disease progression
[6, 8, 25]. Thus additional long-term followup is imperative
for more accurate outcome measurements.
HDCT-AHSCR is particularly attractive for pediatric
brain tumor management, since it may permit omission of
radiotherapy and its devastating neurocognitive sequelae,
particularly in the very young [7, 8, 18]. It also can be used
as a bridging modality for younger patients with radiosen-
sitive lesions. Yet acute toxicity of high-dose chemotherapy
itself may be unacceptable; while the main dose limiting
hematopoietic suppression is reversed by AHSCR, excessive
systemic toxicities including deaths have been reported [1,
20, 22–24]. In addition, modern advanced radiotherapy is
less harmful [18, 26, 27], and its long-term consequences
on the developing brain are presumably comparable to
that caused by high-dose chemotherapy, which may not be
negligible.
HDCT-AHSCR for pediatric brain tumors has been
regularly utilized at the University of California at Los
Angeles (UCLA) since the late 1990s and we have conducted
a retrospective review of consecutively treated patients to
summarizeoursingleinstitution’s experienceforthismodal-
ity. While the limited statistical power and retrospective
characterofthisstudyarelimitations,itallowsthederivation
of valuable ﬁndings concurring with reported predictive
variables and clinical outcome measurements. This is a
reﬂective validation of a heterogeneous and small, yet
representative patient group. It supports the results from
evaluation of toxicity proﬁle of various regimens utilized in a
setting of standardized supportive care delivery.
2. Methods
2.1. Patients. Informed consents were obtained from all
18 patients and/or parents in accordance with the UCLA
Institutional Review Board (IRB# HSPC 10–000126). All
18 consecutive pediatric patients with brain tumors who
underwent HDCT-AHSCR at UCLA from 1999 to 2009
were enrolled in this retrospective clinical review and out-
come analyses (Table 1). The patients’ data on demographic
and clinical characteristics, treatments and disease status
prior to AHSCR, complications after AHSCR, and ﬁnal
outcomes were extracted. For all patients, relevant clinical
information including laboratory results was also retrieved
by the hospital electronic medical record system. In addition
to the electronic medical record, clinical information was
supplemented by reviewing hard copies of patient medical
records.
2.2. Treatment. Once diagnosed with a brain tumor,
accepted standard treatment was initiated for all patients
based on tumor type and stage (Table 2). Indications for
HDCT-AHSCR included young age prohibiting radiation
therapy,recurrent/refractoryorresidualdiseaseafterupfront
treatment, and/or chemosensitive primary tumors with poorJournal of Transplantation 3
Table 2: Surgeries, chemotherapy prior to HDCT-AHSCR, and radiotherapy.
Patient
number
Initial
surgery Initial chemotherapy Salvage chemotherapy Radiotherapy (timing)
1 GTR CDDP, VCR, Lomustine CPM, Topotecan CSI
(pre-recurrence/AHSCR)
2 — CP, VP, Ifos none CSI (post-AHSCR)
3 STR CDDP, VCR, CPM, VP, MTX none None
4 — CP, VP, Ifos none CSI (post-AHSCR)
5 S T R C D D P ,V C R ,C P M ,V P n o n e N o n e
6G T R C D D P ,V C R ,C P M ,V P ,M T X ,
TMZ none None
7G T R C D D P ,V C R ,C P M ,V P ,M T X ,
TMZ none None
8 STR TMZ, CPM ICE, CPM, Topotecan None
9— C P , V P , I f o s I C E CSI (pre-recurrence and
post-AHSCR)
10 GTR CDDP, VCR, CPM, VP none CSI (pre-AHSCR)
11 GTR CDDP, VCR, CPM, VP, MTX none None
1 2 G T R C D D P ,V C R ,C P M ,V P n o n e N o n e
13 STR None TMZ CSI
(pre-recurrence/AHSCR)
14 STR CDDP, VCR, CPM, VP CP, Thiotepa (HDCT) None
15 STR CDDP, VCR, CPM, VP none CSI
(post-AHSCR/recurrence)
1 6 G T R C D D P ,V C R ,C P M ,V P n o n e N o n e
1 7 G T R C D D P ,V C R ,C P M ,V P n o n e N o n e
18 STR CDDP, VCR, CPM, VP none CSI (post-AHSCR)
GTR: gross total resection, STR: subtotal resection, CDDP: Cisplatin, VCR: Vincristine, CP: Carboplatin, VP: Etoposide, Ifos: Ifosfamide, CPM:
Cyclophosphamide, MTX: Methotrexate, TMZ: Temozolomide, CSI: Cerebrospinal irradiation, ICE: Ifos, CP, and VP.
prognoses. Patients with recurrent tumors were also treated
with second-line chemotherapy with or without additional
surgery and radiotherapy ﬁrst, aiming for complete remis-
sion before the HDCT-AHSCR. Patients had at least a
partial response or stable disease prior to HDCT-AHSCR.
Peripheral blood stem-cells were harvested and then used in
all cases as a source of hematopoietic stem-cells. Granulocyte
colony stimulating factor was used for mobilization of
peripheral blood stem-cells, which were collected, then
stored unmanipulated in dimethyl sulfoxide and reinfused
after HDCT.
Eight patients <3 years old who underwent 3 tandem
AHSCR had myeloablative HDCT with carboplatin (CP),
and thiotepa (TT), which were given once daily for 2 days
on days −3a n d−2( Table 3). Seven of these 8 patients
received 3 induction courses each with VCR, cisplatin
(CDDP), cyclophosphamide (CPM) (with MESNA), and
etoposide(VP).Sixoutof9patientswithsingleAHSCRwere
conditioned utilizing CP on days −8, −7, −6; TT and VP
on days −5, −4, −3. Two additional patients with nonger-
minomatous germ cell tumors (NGGCT) received a single
AHSCRafterreceivingHDCTregimensconsistingofTTand
VP once daily on days −5, −4, and −3. Another patient
with pineoblastoma received a single autologous transplant
after HDCT with CPM for 4 days and melphalan for 3 days.
Lastly, one patient with a supratentorial PNET who had 4
tandem AHSCRs received HDCT with CDDP, CPM, and
VCR. Dose modiﬁcation for CP was made for one patient
who had abnormal renal function before the transplant.
Post-AHSCR, patients received standard supportive care
measures, including bactrim and ﬂuconazole for prophylaxis
of pneumocystis jirovecii and opportunistic fungal infec-
tions, respectively. Transfusions of irradiated blood products
were used to maintain hemoglobin level above 8g/dl and
platelet count above 20 × 10e3/µLo rh i g h e rf o ra c t i v e
bleeding for all patients. Granulocyte colony stimulating
factor was utilized posttransplant if the patient had uncon-
trolled neutropenic sepsis or neutropenic fever unresponsive
to antimicrobial agents. Supplemental parenteral nutrition
was used to support patients with severe gastrointestinal
mucositis with diminished caloric intake. Additional tumor-
directed or palliative therapy was administered to three
patients after transplant that had further residual, recurrent,
or progressive tumors. Patient no. 9 with NGGCT received4 Journal of Transplantation
Table 3: HDCT-AHSCR and outcome.
Patient
number
Age at ﬁrst
AHSCR
(years)
Status at
AHSCR
HDCT prior to
AHSCR
Number of
AHSCR
Recurrence after
transplant Outcome
Latest
Lansky/Karnovsky
performance scores
1 15.2 PR ¶CP, TT, VP 1 No Deceased —
2 16.4 CR VP, TT 1 No Alive 100
31 . 6 C R ¶CP, TT, VP 1 No Alive 90
4 17.8 PR VP, TT 1 No Alive 90
53 . 2 P R ∗CP, TT 3 Yes Alive 90 (Prior to
recurrence)
65 . 9 C R ¶CP, TT, VP 1 No Alive 90
71 . 2 C R ¶CP, TT, VP 1 No Alive 90
82 . 8 S D ∗CP, TT 3 Yes Alive 90
9 20.0 SD ¶CP, TT, VP 1 Yes Deceased —
10 4.9 CR CDDP,VCR,CPM 4 No Alive 100
11 2.3 CR ¶CP, TT, VP 1 No Alive 90
12 2.5 CR ∗CP, TT 3 No Alive 100
13 15.3 SD CPM, Melphalan 1 Yes Deceased —
14 0.7 SD ∗CP, TT 3 Yes Deceased —
15 2.7 PR ∗CP, TT 3 Yes Deceased —
16 2.4 CR ∗CP, TT 3 No Alive 100
17 2.5 CR ∗CP, TT 3 No Alive 100
18 2.0 CR ∗CP, TT 3 No Alive 90
PR: Partial remission, CR: Complete remission, SD: Stable disease. ¶CP, TT, VP: Carboplatin (500mg/m2/dose or 16.7mg/kg/dose for <3y/o)ondays−8,
−7, and−6; Thiotepa (300mg/m2/dose or 10mg/kg/dose for < 3y/o) and Etoposide (250mg/m2/dose or 8.3mg/kg/dose for <3y/o)ondays−5, −4, and−3,
∗CP, TT: Carboplatin 17mg/kg/dose, and Thiotepa 10mg/kg/dose, given IV over 2 hours once daily for 2 days on days −3a n d−2, VP, TT: Thiotepa
300mg/m2/dose and Etopposide 500mg/m2/dose once daily on days −5, −4, and −3, CDDP: Cisplatin, CPM: Cyclophosphamide, and VCR: Vincristine.
additional radiation therapy for palliation after recurrence
post-AHSCR (Table 2), patient no. 5 started treatment with
irinotecan, bevacizumab, and TMZ, and patient no. 8 was
treated with irinotecan and TMZ for palliation.
2.3. Deﬁnitions. Complete remission (CR) was deﬁned as re-
solution of initially demonstrable tumors without the
appearance of new diseased areas measured by MRI. In
four cases, minimal residual heterogeneous post-treatment
lesions enhancing on MRI were suspicious for refractory
disease and were rebiopsied, which demonstrated absence
of viable tumor and conﬁrmed CR. Partial remission (PR)
and stable disease (SD) were deﬁned as greater or less
than a 50% decrease in the product of the two largest
perpendicular diameters of the tumor, respectively. If the
initial cerebrospinal ﬂuid (CSF) cytology was positive, two
consecutively negative CSF cytology exams were required
to document CR or PR. Repeatedly positive CSF without
persistent increase in cell count was an additional ﬁnding
that qualiﬁed for stable disease. Progressive disease was
deﬁnedasanincreaseof>25%intumorareawithmaximum
perpendicular diameters in any site of residual disease area
compared to immediate pretreatment area or compared to
area of best prior response at that site, the appearance
of a new demonstrable lesion, or the conversion of CSF
cytology from negative to positive. Neutrophil engraftment
w a sd e ﬁ n e da sa na b s o l u t en e u t r o p h i lc o u n tr e c o v e r yf r o m
nadir to 0.5 × 10e3/µLo rg r e a t e rf o r2c o n s e c u t i v ed a y s .
Toxicity grading was conducted based on the standard
National Cancer Institute toxicity criteria. Progression-free
survival was assessed from the date of the ﬁrst AHSCR to the
date of disease relapse or progression. Overall survival was
assessed from the date of ﬁrst AHSCR to the date of death.
2.4. Statistics. Both progression-free survival (PFS) and
overallsurvival(OS)wererelatedtotheexplanatoryvariables
using a Cox proportional hazards model and illustrated
with the Kaplan-Meier method as implemented by Stata
8.0 (StataCorp). Multivariate logistic regression models were
performed to control for extent of resection and disease
status prior to AHSCR. Analysis of variance (ANOVA)
was used to test the signiﬁcance of toxicity diﬀerences
between single versus ≥3 AHSCR regimens. This was further
conﬁrmed by the nonparametric K-Wallis test. All P values
were two sided and P<. 05 was considered signiﬁcant.
3. Results
3.1. Patient Characteristics. A total of 18 patients were
identiﬁedinourcomprehensivePediatricBloodandMarrow
Transplant database, who had HDCT-AHSCR from 1999–
2009 for brain tumor treatment. Patient characteristics areJournal of Transplantation 5
presented in Table 1. Patients were 0.4–19 years old at
diagnosis (mean 5.6, median 2.3 yrs), and male: female ratio
was 2:1. Two thirds of the patients had neuronal/embryonal
tumors (7 medulloblastomas, 4 PNETs, and a pineoblas-
toma), two patients had anaplastic glial tumors (an ependy-
moma and an oligodendroglioma), one patient had a
neurocytoma, and three had NGGCT. Patients with NGGCT
were>15y/o,andthemajorityoftheremainingpatientswere
younger (<5–3y/o). Locations of these lesions are shown in
Table 1. Only four patients had recurrent lesions; the rest
had primary tumors. Chang staging principles applied to
all tumors and revealed 4 patients with M2, four with M3
(including positive CSF cytology and focal, subarachnoid, or
leptomeningeal spreads) and the remaining with M0 status
as a highest stage at any time prior to HDCT-AHSCR.
3.2. Treatment. Most of the patients had initial surgical
intervention:eightendedupwithgrosstotalresection(GTR)
on ﬁrst attempt, 7 had subtotal resections (STR), 2 of
which were followed by GTR, and 3 NGGCT were not
resected initially (one eventually had GTR after recurrence)
(Table 2). A total of 11 patients had ventriculo-peritoneal
shunt placement.
Various agents and combinations were utilized for initial
chemotherapy as shown in Table 2. With the exception
of one patient with pineoblastoma, who was treated with
initial radiotherapy and subsequent temozolomide only after
recurrence (prior to HDCT), the rest received chemotherapy
upfront. This patient with pineoblastoma was conditioned
with CPM and Melphalan for a single AHSCR. Three
NGGCT patients received initial VP, ifosfamide, and CP
× 6 courses, one of whom also got radiotherapy prior to
recurrence. These patients with NGGCT were conditioned
with VP/TT (+CP for patient no. 9 with recurrent NGGCT)
for single AHSCR. One older patient (no. 1) with medul-
loblastoma was initially treated at an outside hospital with
a combination of CDDP, VCR, Lomustine, and radiotherapy
prior to recurrence. The patient with recurrent neurocytoma
received initial chemotherapy with TMZ and CPM.
The remaining 12 patients were initially treated with at
least three courses of VCR, CDDP, CPM, and VP; 4 of whom
had5courseswithadditionofMTX,and2ofthese4patients
also received TMZ. Seven out of these 12 patients (as well as
patient no. 8 with recurrent neurocytoma) received 3 cycles
of high-dose CP and TT, each followed by AHSCR, and
one of the 12 received a diﬀerent HDCT regimen and × 4
AHSCRs as described in the methods section and shown in
Table 3. Four patients who had additional TMZ and/or MTX
to initial chemotherapy and patient no.1 also received VP, in
addition to CP and TT (Table 3) during HDCT for AHSCR.
Four patients with recurrent disease also received additional
salvage therapy prior to AHSCR as shown in Table 2. For one
of them, HDCT with TT and CP for AHSCR served also as a
salvage regimen for residual/SD medulloblastoma.
In summary, half of our patients received ≥3t a n d e m
AHSCR with generally less prior chemotherapy exposure
during induction, and milder HDCT per each AHSCR.
The other half got stronger induction chemotherapy and
more intensive HDCT prior to their single AHSCR. This
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Figure 1: Kaplan-Meier survival estimates for PFS and OS, all
patients (n = 18).
dichotomization among the patients allowed us to evaluate
for diﬀerences of toxicity proﬁles and test the hypothesis that
toxicity proﬁles of single AHSCR versus ≥3 tandem AHSCR
regimens are diﬀerent.
The median diagnosis to transplant time was 6 months
(mean: 1 year). The average number of infused CD34+cells
per kg per AHSCR was 20 × 10e6 (range: 2 to 100 ×
10e6). The average time between the tandem courses was
29 ± 7d a y s( M e a n± SDEV, range 21–53) (this is versus
intended 21 days, mostly due to delayed hematopoietic
engraftment/count recovery). Neutrophil engraftment was
estimated by an average of 17 ± 8 (SDEV) days post-
transplant. Ten patients did not receive any radiotherapy
during their entire treatment at the time of our analyses.
Three patients (no. 1, 10, and 13) received cerebrospinal
radiotherapy prior to AHSCR, four patients (no. 2, 4, 15,
and 18) received cerebrospinal radiotherapy post-AHSCR,
and one patient (no. 9) received radiotherapy both pre- and
post-AHSCR.
3.3.OutcomeAnalyses. Thefollow-updurationswere3 ±2.4
years (mean ± SDEV, range 0.9–8.9, and median: 2 years)
afterdiagnosisand2 ±2.4yearsaftertransplant(range0.05–
8.5, and median: 1.1 years). The probabilities of three-year
PFS and OS from AHSCR were 60.5%± 16 (mean ± Std.
Error) and 69.3% ± 11.5, respectively, (Figure 1).
We sought out associations between the clinical outcome
andthefollowingparameterstoidentifypotentialprognostic
predictors: age, gender, tumor type and staging, extent
of surgical resection, chemotherapy regimens, radiation
therapy, disease status prior to AHSCR, as well as grade
of toxicity as another measurable endpoint. Heterogeneous
patient characteristics and tumor histotypes along with
small numbers were restrictive for appropriate statistical
power for some relevant analyses, such as testing diﬀerent
regimens within tumor subtypes. Nevertheless, in univariate
analyses we found no general associations between the age,6 Journal of Transplantation
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Figure 2: Kaplan-Meier survival estimate for PFS for patients
with initial subtotal resection (STR) (n = 7) versus those with
initial gross total resection (GTR) (n = 8). Three patients with
nongerminomatous germ cell tumors did not have initial surgery
and are not included in this analysis.
gender, tumor type/staging, HDCT regimens (single versus
≥3 AHSCR), radiation therapy, toxicity grade, and clinical
outcome expressed either as PFS and OS for all 18 patients.
Our signiﬁcant ﬁndings included a strong correlation
between the extent of initial surgical resection and PFS
(Figure 2), as well as the disease status prior to AHSCR and
clinical outcome (both PFS and OS, as shown in Figures 3(a)
and 3(b),r e s p e c t i v e l y ) .Figure 2 demonstrates the Kaplan-
Meier curves for PFS of 15 patients with initial resection
(excluded are 3 NGGCT patients), separated according to
GTR versus STR. Patients with initial STR have signiﬁcantly
worse PFS than those with GTR (P<. 001, Hazard Ratio
(HR) = 9, and 95% Conﬁdence Interval (CI) >10− >10 per
Cox proportional Hazards regression).
Figures 3(a) and 3(b), respectively, depict Kaplan-Meier
curves for PFS and OS for all 18 patients, based on their
disease status prior to AHSCR. Patients with CR prior to
AHSCR (either biopsy proven negative or not excluded
minimal residual disease) have sustained >3yr PFS and
OS of 100%, whereas most patients with PR or SD have
succumbed due to disease progression (one patient died
from therapy-related toxicity). Cox proportional Hazards
regression demonstrated P<. 001, HR = 6.52, with 95% CI
= 2.67–15.9 for PFS, and P<. 001, HR = 4.98, with 95% CI =
1.86–13.4, for OS.
Multivariate analysis was performed to test interdepen-
dence between the extent of initial surgical resection and
disease status prior to AHSCR as predictors of PFS. This
demonstrated, that when adjusted for each other, GTR
independently sustains its predictive signiﬁcance with P<
.001, HR > 10, CI> 10− > 10, with CR prior to AHSCR
approaches being independently signiﬁcant (P = .056, HR
= 2.8, CI = 0.97–7.9). In concordance, 87.5% of patients with
P<. 001
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Figure 3: Kaplan-Meier survival estimate for PFS (a) and OS (b)
according to disease status prior to AHSCR.
GTR had CR prior to AHSCR and 70% of CR patients had
GTR on initial resection.
3.4. Toxicity. Table 4 demonstrates detailed toxicity data for
all18patientsasgradedbyNationalCancerInstitutecriteria.
This data comprehensively captures toxic episodes for all
listed categories within 30 days after AHSCR. In addition,
all patients experienced grade 3-4 hematopoietic toxicities
as anticipated requiring irradiated blood product support.
As summarized in Figure 4, patients with ≥3 AHSCR
experienced less toxicity in general, whereas patients who
received single AHSCR had more toxic episodes and 1 toxic
death.
To quantify and compare toxicity data, we conditionally
scored all patients’ toxicity other than hematopoietic sup-
pression; those who had no other grade 3 or higher toxicity
were scored with 0 (n = 4), fever and neutropenia, infectious
complications were scored with 1 (n = 3); and fever and
neutropenia with at least one more organ system grade 3 orJournal of Transplantation 7
Table 4: Toxicity.
Patient
number Infectious complications GI mucositis Liver, transaminitis
(hyperbilirubinemia) Metabolic/renal Other
1 Grade 4, F&N Grade 3 Grade 3 (Grade 3)
Grade 4
(elevated
BUN/Creatinine)
Neuro: Grade 3, Altered mental
status
Cardiovascular: Grade 4,
Hypotension
Pulmonary: Grade 4, Respiratory
failure
Skin: Grade 4, TEN
2 Grade 3, F&N Grade 3
3 Grade 3, F&N Grade 3 Grade 3
4 G r a d e3 ,F & N ,H e r p e t i c
stomatitis Grade 3 Endo: Exacerbation of baseline
panhypopituitarism
5G r a d e 3 , F & N
6 Grade 3, F&N, Serratia
UTI Grade 3 Grade 4, Hypokalemia CV: Grade 1, Prolonged QTC
Neuro: Grade 3, Hearing loss
7
G r a d e3 ,F e v e r ,s e p s i sw i t h
Pseudomonas and
Klebsiella
Grade 3
8
Grade 3, F&N, UTI with
Vancomycin-resistant
enterococcus
Grade 3 Grade 2 Neuro: Grade 2, Self-resolved
seizure
9 Grade 3, F&N Grade 3
10 Grade 1, Decreased GFR Neuro: Grade 1,
High-frequency hearing loss
11 Grade 3, F&N,
Eenterococcus UTI Grade 3
12 Grade 1,
Hypomagnesemia
Neuro: Grade 1,
High frequency hearing loss
13 Grade 3, Pneumonia Grade 3
Grade 1, Hypokalemia
Grade 3, Hyponatremia
(not SIADH)
14 Grade 2, Fever
Grade 3, F&N Grade 2 (Grade 3) Neuro: Grade 4, Status epilepticus
15 Grade 1,
Hypomagnesemia
16
17 Grade 3, F&N Grade 1,
Hypomagnesemia
18 Grade 3, Zoster infection
F&N: Fever and neutropenia, UTI: Urinary tract infection, GFR: Glomerular ﬁltration rate, SIADH: Syndrome of inappropriate antidiuretic hormone
hypersecretion, TEN: Toxic epidermal necrolysis.
higher toxicity (excluding hematopoietic) were scored with
2( n = 11). These scores were ﬁrst used as variables to
perform ANOVA between single AHSCR and ≥3 AHSCR
groups, and it conﬁrmed the signiﬁcant diﬀerence (P<. 001,
at ≥3 AHSCR mean toxicity score (±SDEV) was 0.78 ±
0.83, and at single AHSCR mean toxicity score was 2 ± 0).
Furthermore, these results were conﬁrmed by performing
the nonparametric Kruskal-Wallis test between two groups
(P = .0054).
There was no formal neuropsychological testing for most
patients; however, Lansky-Karnofsky performance scores
demonstrated that all survivors had satisfactory functional
status (Table 3).
4. Discussion
This retrospective study demonstrates that pediatric brain
tumor patients treated with HDCT-AHSCR are most likely
to have favorable outcome if patients achieved CR (either
biopsy proven or by radiologic criteria, that is, minimal
residual disease not excluded) at the time of AHSCR.
Gross total resection, which has historically been one of8 Journal of Transplantation
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the most prominent favorable prognosticators, [22, 28], was
associatedwithCRinourstudyandindependentlypredicted
PFS. In contrast, patients with SD at the time of transplant
and especially those who had progression prior to transplant
had the poorest chance of survival when treated by HDCT-
AHSCT. Our data also suggests that some of the patients
with PR without overt progression prior to transplant still
may be salvaged by HDCT-AHSCT. These ﬁndings are in
concordance with multiple previous reports [8, 22, 23]. Our
60% PFS and 69% OS rates are also comparable or superior
with reported outcome data [6, 7, 12, 18, 19, 21, 22]. These
survivalratesrationalizetheuseofthismodalityforpediatric
brain tumor patients with poor prognosis, with estimated
EFS/OSgenerallylessorequalthan50–40% atbest, if treated
with nonmyeloablative therapies [1, 5, 23]. In our study, it is
not possible to conclude whether a portion of the included
patients already were cured without the HDCT-AHSCR.
International consensus meetings have concluded that the
precise role of HDCT-AHSCR in pediatric brain tumors can
only be determined in randomized trials.
The heterogeneity of tumor types and treatment regi-
mens prevented the development of any strong conclusions
based on the negative ﬁndings of our retrospectively stud-
ied small patient group. Particularly, subgrouping patients
into embryonal tumors (compared with others) and/or
further subdivision according to treatment regimens result
in small numbers, which cannot be utilized for conclusive
analyses. Nevertheless, only 25% (3/12) of patients with
embryonal tumors experienced recurrence after AHSCR,
compared to 60% (2/3) of patients with glial/mixed lesions
(Table 3), an observation that concurs with well-established
knowledge that medulloblastomas and PNETs have better
responsiveness [7, 8, 11, 12, 14, 19, 22, 24] to this modality
compared to glial tumors [6, 11, 18–20, 22]. In addition, we
cannot exclude that more intensive induction with stronger
single HDCT/ AHSCR harbors some therapeutic advantage
over less intensive induction and “milder” HDCT with ≥3
AHSCR for embryonal tumors, since 2 out of 3 recurrences
in 12 embryonal tumors occurred among the 6 patients, who
got ≥3 AHSCR. Yet, our one young patient with anaplastic
ependymoma is in sustained CR 4.3 yrs post-triple tandem
AHSCR regimen (no radiation), despite the literature which
reports very poor outcome (5-yaer EFS 12%) for those
treated with single AHSCR [20].
While the aforementioned comparisons of clinical out-
come between single and ≥3 AHSCR regimens in subgroups
lack signiﬁcant power, our toxicity data analyses are more
robust (assuming that tumor type is unrelated to toxicity).
There are no randomized studies between regimens with
single versus ≥3 AHSCR reported in the literature. However,
up to 10–20% toxic mortality has been documented in series
with stronger thiotepa-based regimens and single-AHSCR
[19, 20, 22–24], whereas a larger medulloblastoma study
with milder cyclophosphamide-based chemotherapy and up
to 4 AHSCRs had no protocol-related deaths [12]. Our
data support these ﬁndings in that our only toxic death
occurredinthesingleAHSCRgroup(1/9,11%).Inaddition,
regimens with ≥3 AHSCR were tolerated much better
with signiﬁcantly fewer toxic episodes (Table 4, Figure 4).
It appears that repetitive administration of TT at doses
comparable to that used in single transplant (which utilizes
concomitant VP in HDCT) may decrease nonhematologic
toxicity and allow administration of a greater cumulative
drug dose. Whether this reduced toxicity is accompanied
with decreased eﬃcacy still remains to be seen.
The major papers on transplant in embryonal brain
tumors in children are reported on the Head Start program
byFangusaro et al., which is referenced above [8]. The
other approach to embryonal recurrent tumors is enhanced
delivery by intra-arterial chemotherapy and osmotic blood-
brain barrier disruption (IA/BBBD), as recently reviewed in
Cancer by Jahnke et al. [29]. Comparison of these two larger
series with regards of eﬃcacy demonstrates comparable
disease-free and OS survival rates of around 40% and 50%,
respectively,ataboutthe3-yearmark.Ourpatients’outcome
with an almost 60% PFS and 70% OS at 3 years may seem
promising; however, many of the common critical objections
apply. First, only 2 of our 12 patients with embryonal tumors
had recurrent tumors; the remaining had primary tumors
(Table 1). Second, our inclusion criterion for this study is the
high-dose therapy/autologous rescue and not the intention
totreat.Moreover,ourstudyisnonrandomizedandfollowup
is rather short. Nevertheless, our survival curves apparently
are reaching their plateau, and we anticipate ≥50% long-
term survivorship. In general, small, heterogeneous, and
selected study groups hamper studies in this ﬁeld. According
to newer data, medulloblastomas with particular histological
features and molecular signatures may have a more favorable
prognosis[30],buttheretrospectivenatureofourstudydoes
not allow us to perform these analyses.
Toxicities observed in our patients were similar to
pediatric supratentorial PNET patients reported by Fan-
gusaro et al. [8] and for children with medulloblastoma [31].
These mainly involved grade 3-4 hematopoietic toxicities,Journal of Transplantation 9
Table 5: Comparison of nonneurological toxicity of three studies.
Study IA/BBBD for embryonal/germ
cell tumors/Jahnke et al. [29]
High-dose chemotherapy and
autologous transplantation for
sPNETs/Fangusaro et al. [8]
Current series
Number of patients 54 43 18
Hematopoietic ∼35% 100% 100%
Fever and neutropenia 24% 70% 60%
Mucositis —
Frequent in patients
receiving
methotrexate
56%
Toxic mortality
—
(No IA/BBBD
treatment-related deaths were
reported; all 3 patients who
died from delayed
neurotoxicity received CSI).
5%
(infection associated)
6%
(multiorgan
failure)
IA/BBBD: Intra-arterial Chemotherapy and Osmotic Blood-Brain Barrier Disruption.
sPNETs: supratentorial Primitive Neuroectodermal Tumors.
CSI: Cerebrospinal Irradiation.
episodes of febrile neutropenia and, mucositis, often requir-
ing narcotics. Transient liver transaminase elevations were
alsoobservedduringchemotherapy.Incontrast,inIA/BBBD
study reported hematopoietic suppression and neutropenic
fever to a lesser extent [29], highlighting the advantage of
less systemic toxicity by this modality. Table 5 summarizes
selected nonneurological toxicities of these three studies
in general. In addition, regarding neurological toxicities,
IA/BBBDwasreportedlyassociatedwithneurotoxicepisodes
in approximately 30% of patients with a vast majority with
reversible neurologic deﬁcit lasting >24 to 48 hrs. This is
comparabletotheneurotoxicityobservedforour18patients,
a third of whom have experienced neurological adverse
eﬀects in one form or another, including grades 1 and 3
hearing loss (Table 4). In comparison, approximately 60% of
patients sustained high-frequency hearing loss necessitating
a reduction or elimination of cisplatin in study reported by
Fangusaro et al. [8]. Patients in the IA/BBBD study received
heterogeneous sodium thiosulfate regimens, and an accurate
comparison of ototoxicity was not feasible [29].
A number of mechanisms by which dose-intensive
chemotherapy might help include steep dose response
curve of alkylating agents [1–3, 32], blood-brain-barrier
penetration [33, 34], and overcoming intrinsic resistance of
hypothetical subpopulation(s) of cells such as brain tumor
initiating cells [35, 36]. While HDCT-AHSCR may oﬀer
these advantages, we conclude that further intensiﬁcation
of regimens using HDCT likely has reached the point of
maximum clinical toxicity, while resulting in diminished
return, necessitating the development of newer modalities
to improve upon the eﬃcacy of brain tumor therapy.
Recent advances in the molecular pathology of malignant
glioma and medulloblastoma provide more opportunities
for targeting brain tumors [30, 37]. This knowledge might
be used for proposed biological modiﬁcations following
HDCT-AHSCR for pediatric brain tumors [38], and pedi-
atric brain tumor derived neurospheres may also provide
an excellent predictive model for preclinical explorations for
such important endeavors [39].
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